6533b82cfe1ef96bd128ed98

RESEARCH PRODUCT

A Definitive Pharmacophore Modelling Study on CDK2 ATP Pocket Binders: Tracing the Path of New Virtual High-Throughput Screenings

Giulia CullettaAnna Maria AlmericoLuca LivecchiMarco Tutone

subject

CDK20301 basic medicineComputer scienceATP pocketCancer therapyComputational biologyMolecular dynamicsTracingCommon hits approachInhibitory Concentration 5003 medical and health sciencesMolecular dynamicsAdenosine Triphosphate0302 clinical medicineNeoplasmsDrug DiscoveryHumansProtein Kinase InhibitorsThroughput (business)Eukaryotic cellMM-GBSABinding SitesbiologyCyclin-Dependent Kinase 2Cyclin-dependent kinase 2High-Throughput Screening AssaysMolecular Docking Simulation030104 developmental biology030220 oncology & carcinogenesisPharmacophore modellingPath (graph theory)biology.proteinPharmacophoreProtein Binding

description

Cyclin Dependent Kinases-2 (CDK2) are members of serine/threonine protein kinases family. They play an important role in the regulation events of the eukaryotic cell division cycle, especially during the G1 to S phase transition. Experimental evidence indicate that excessive expression of CDK2s should cause abnormal cell cycle regulation. Therefore, since a long time, CDK2s have been considered potential therapeutic targets for cancer therapy. In this work, onehundred and forty-nine complexes of inhibitors bound in the CDK2-ATP pocket were submitted to short MD simulations (10ns) and free energy calculation. Comparison with experimental data (K<sub>i</sub>, K<sub>d</sub> and pIC<sub>50</sub>) revealed that short simulations are exhaustive to examine the crucial ligand-protein interactions within the complexes. Information collected on MD simulations of protein-ligand complexes has been used to perform a molecular modelling approach that incorporates flexibility into structure-based pharmacophore modelling (Common Hits Approach, CHA). The high number of pharmacophore models resulting from the MD simulation was thus reduced to a few representative groups of pharmacophore models. The performance of the models has been assessed by using the ROC curves analysis. This definitive set of validated pharmacophore models could be used to screen in-house and/or commercial datasets for detection of new CDK-2 inhibitors. We provide the models to all the researchers involved in this field.

https://doi.org/10.2174/1570163816666190620113944